Please note: AABB reserves the right to make updates to this program.
Thursday, April 27, 2017
2:00 – 3:30 PM (ET) 7:00 – 8:30 PM (GMT)
Master Program Number: 130 (see program format numbers below under Registration)
Educational Track: Technical/Clinical
Topic: Patient Blood Management
Intended Audience: Technologists, Nurses, Managers/Supervisors, Physicians, Perfusionists
Teaching Level: Intermediate
Director/Moderator: Mark Friedman, DO, Medical Director, Blood Bank and Transfusion Service / Assistant Professor of Pathology, Mount Sinai Health System / Icahn School of Medicine at Mount Sinai, New York, NY
Speaker: Kyle Annen, DO, Medical Director, Blood Bank and Transfusion Service, Mount Sinai Beth Isreal Medical Center, Assistant Professor of Pathology, Icahn School of Medicine, New York, NY
After participating in this educational activity, participants should be able to:
- Understand the key differences between neonatal and adult hemostasis.
- List the differential diagnosis for the bleeding neonate at less than 24 hours of age, 1 week of age, and greater than 2 weeks of age.
- Discuss the diagnosis and treatment of neonatal alloimmune thrombocytopenia (NAIT).
- Review the approach to using CMV-safe vs. leukocyte-reduced blood products in the neonatal population.
This program will focus on special coagulation and transfusion needs of the neonate, an important aspect of patient blood management not to be overlooked. Neonatal coagulation is different than that of the adult, and thus requires special attention. The speaker will provide an overview of the major coagulation and bleeding complications that occur in the neonatal population and address common pitfalls. Recently-published clinical updates on the management of neonatal alloimmune thrombocytopenia (NAIT) and the use of CMV-safe blood products will be reviewed.
| || ||
|Single Viewer: Live||
|Single Viewer: On-Demand||
|Group Viewing: Live||
|Group Viewing: On-Demand||
|Group Viewing: Live & On-Demand||